Send to

Choose Destination
Wien Med Wochenschr. 2010 Dec;160(21-22):539-46. doi: 10.1007/s10354-010-0844-8.

Ginkgo biloba in Alzheimer's disease: a systematic review.

Author information

Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany.

Erratum in

  • Wien Med Wochenschr. 2011 Feb;161(3-4):104. Garrido, Marcial V [corrected to Velasco Garrido, Marcial].


This systematic review determines the benefit of treatment with Ginkgo biloba (Ginkgo) in Alzheimer's disease (AD) concerning patient-relevant outcomes. Bibliographic databases, clinical trial and study result registries were searched for randomized controlled trials (RCTs) in patients with AD (follow-up ≥16 weeks) comparing Ginkgo to placebo or a different treatment option. Manufacturers were asked to provide unpublished data. If feasible, data were pooled by meta-analysis. Six studies were eligible; overall, high heterogeneity was shown for most outcomes, except safety aspects. Among studies administering high-dose Ginkgo (240 mg), all studies favour treatment though effects remain heterogeneous. In this subgroup, a benefit of Ginkgo exists for activities of daily living. Cognition and accompanying psychopathological symptoms show an indication of a benefit. A harm of Ginkgo is not evident. An estimation of the effect size was not possible for any outcome. Further evidence is needed which focuses especially on subgroups of AD patients.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center